BioLineRx explained

BioLineRx Ltd.
Type:Public
Traded As:NASDAQ:
Location City:Modiin
Location Country:Israel
Key People:Philip Serlin (CEO)
Industry:Biotechnology
Services:Drug development
Owners:Novartis (12.8%, 2014)
Footnotes:[1]

BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.

Corporate history

The firm was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors.[2] It executed an initial public offering on the Tel Aviv Stock Exchange in February 2007, raising 211 million NIS ($50 million) – the TASE's largest biotech IPO until that time.[3] [4] In July 2011 BioLine's ADRs began trading on the NASDAQ Capital Market.[5] [6] In January 2012, the firm announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment for Hepatitis C.[7] At the end of 2014, Novartis acquired a 12.8% stake in the company as a strategic move to gain access to Israeli-sourced drug candidates.[8]

Management

Morris Laster, (M.D.) an alumnus of. Downstate Medical Center, was CEO of BioLineRx until 2009. He was replaced by Kinneret Savitsky, alumnus of Tel Aviv University early in 2010.[9] Savitsky was replaced as CEO by BioLine COO Philip Serlin on October 10, 2016.

Operations

BioLineRx is a drug development company When promising compounds are discovered, the firm leads them through preclinical trials and engages other companies to further develop them into commercializable drugs.[10] The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound.[11] In 2010, BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over by Ramius LLC.[12]

Pipeline

Below is a partial list of drug compounds in various stages of development by BioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited.

See also

External links

Notes and References

  1. Web site: BLRX Profile: BioLineRx Ltd. Stock. Yahoo! Finance. 28 November 2011. 2011.
  2. News: Grayeff. Yigal. 13 January 2005. BioLineRx signs 3 deals to develop drugs. The Jerusalem Post. dead. 28 November 2011. https://web.archive.org/web/20100203030129/http://www.ivc-online.com/ivcWeeklyItem.asp?articleID=2656. 3 February 2010. IVC Research Center.
  3. News: Cohen. Omri. 7 February 2007. Biotech comes of age: Bioline floats at half-billion shekel market cap. TheMarker. 28 November 2011. Bioline Therapeutics today pulled off its initial public offering in Tel Aviv, raising NIS 211 million at a company valuation of NIS 494 million, making this the biggest flotation by a biotechnology company in local history..
  4. News: Rheinheimer. Laura. 8 February 2007. BioLineRx raises $50m. in TASE's largest biomedical IPO. The Jerusalem Post. 28 November 2011. BioLineRx Ltd. on Wednesday priced the largest ever initial public offering of a biomedical company on the Tel Aviv Stock Exchange, raising a total of NIS 211 million, or $50m..
  5. News: 25 July 2011. BioLineRx ADRs Begin Trading on NASDAQ. 27 April 2019.
  6. News: Cohen. Tova. 24 July 2011. BioLineRX ADRs to begin trading on Nasdaq Monday. Reuters. Magnowski. Daniel. 30 June 2017. 24 September 2015. https://web.archive.org/web/20150924154320/http://www.reuters.com/article/2011/07/24/biolinerx-adr-idUSLDE76N01720110724. live.
  7. News: Wang. Lu. 24 January 2012. Achillion, BioLineRx, J&J Snack, Rubicon: U.S. Equity Movers. Bloomberg News. dead. https://web.archive.org/web/20120124181829/http://www.businessweek.com/news/2012-01-24/achillion-biolinerx-j-j-snack-rubicon-u-s-equity-movers.html. 24 January 2012.
  8. News: 16 December 2014. Novartis Makes $10M Investment in BioLineRx. 35. 9. Genetic Engineering & Biotechnology News. 2. Industry Watch.
  9. Web site: Kinneret Livnat Savitsky Ph.D.: Executive Profile & Biography. 21 February 2015. Bloomberg Business.
  10. News: Brinn . David . BioLineRx—Israel's biotech supermarket . 28 November 2011 . ISRAEL21c . 3 June 2007 . dead . 5 April 2012 . https://web.archive.org/web/20120405235441/http://www.israel21c.org/health/biolinerx-israel-s-biotech-supermarket .
  11. News: Habib-Valdhorn. Shiri. BiolineRX earns $10m milestone payment. https://archive.today/20120803014242/http://www.globes.co.il/serveen/globes/docview.asp?did=1000555803&fid=1725. dead. 3 August 2012. 28 November 2011. Globes. 28 April 2010.
  12. News: Weinreb. Gali. BiolineRX and Cypress cancel schizophrenia drug agreement. 28 November 2011. Globes. 11 May 2011. dead. https://web.archive.org/web/20110615064401/http://www.globes.co.il/serveen/globes/docview.asp?did=1000644520&fid=1725. 15 June 2011.
  13. News: BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain. dead. https://web.archive.org/web/20150926232047/http://www.biolinerx.com/default.asp?pageid=16&itemid=284. 2015-09-26.
  14. News: Israeli co to hold clinical trial for treatment of Schizophrenia in India. 28 November 2011. The Hindu Business Line. 24 November 2011. Jerusalem.
  15. BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain . 28 November 2011 . . 13 September 2011 . . BioLineRx .
  16. News: Bioline looks to heart attack treatment clinical trial. https://archive.today/20120803143138/http://www.globes.co.il/serveen/globes/docview.asp?did=1000626251&fid=1725. dead. 3 August 2012. 28 November 2011. Globes. 27 February 2011.
  17. News: US company buys exclusive license for Israeli heart attack drug for $285 million. 28 November 2011. Israel21c. 8 July 2009.
  18. Web site: Other . www.biolinerx.com . dead . https://web.archive.org/web/20161202235534/http://www.biolinerx.com/default.asp?pageid=96&itemid=47 . 2016-12-02.
  19. News: Wrobel. Sharon. Bioline RX Gets European Device Confirmation for Bl-5010 Drug. 28 November 2011. Bloomberg. 15 September 2011.
  20. Web site: BioLineRx has acquired the rights to compound BL-7040 from Yissum and Prof. Soreq. The Hebrew University of Jerusalem. The Edmond and Lily Safra Center for Brain Sciences. 28 November 2011. 27 June 2011. https://web.archive.org/web/20110712214142/http://elsc.huji.ac.il/content/biolinerx-has-acquired-rights-compound-bl-7040-yissum-and-prof-soreq. 12 July 2011. dead.
  21. News: BioLineRx signs pact with Genoscience & RFS Pharma to develop and commercialize BL-8030 to treat hepatitis C. 8 February 2012. Pharmabiz.com. 8 February 2012. Jerusalem, Israel. dead. https://web.archive.org/web/20150221003613/http://pharmabiz.com/NewsDetails.aspx?aid=67413&sid=2. 21 February 2015.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "BioLineRx".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.